Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group-Reference-Cited by-同舟云学术

Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group

Published:2017-08-14 Issue:12 Volume:31 Page:2833-2837
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Hoechstetter M A,Busch R,Eichhorst B,Bühler A,Winkler D,Eckart M J,Vehling-Kaiser U,Schimke H,Jäger U,Hurtz H J,Hopfinger G,Hartmann F,Fuss H,Abenhardt W,Blau I,Freier W,Müller L,Goebeler M,Wendtner C M,Bahlo J,Fischer K,Bentz M,Emmerich B,Döhner H,Hallek M,Stilgenbauer S

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/leu2017246.pdf

Reference15 articles.

1. Siegel RL, Miller KD, Jemal A . Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7–30.

2. Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 1998; 338: 1506–1514.

3. Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C . Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 1986; 62: 567–575.

4. Rozman C, Montserrat E, Rodríguez-Fernández JM, Ayats R, Vallespí T, Parody R et al. Bone marrow histologic pattern—the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 1984; 64: 642–648.

5. Langenmayer I, Nerl C, Knauf W, Adorf D, Hallek M, Dietzfelbinger H et al. Interferon alpha 2b in the treatment of early stage CLL with risk for progression. Results of a randomized multicenter study. Br J Haematol 1996; 94: 362–369.

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Tower of Babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS;Seminars in Hematology;2024-01

2. High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLL;HemaSphere;2023-09-15

3. The ‘inbetweeners’: living on a watch and wait approach for chronic lymphocytic leukaemia – a qualitative study;British Journal of Nursing;2023-09-07

4. XPO1 mutations identify early‐stage CLL characterized by shorter time to first treatment and enhanced BCR signalling;British Journal of Haematology;2023-08-14

5. Additional lesions identified by genomic microarrays are associated with an inferior outcome in low‐risk chronic lymphocytic leukaemia patients;British Journal of Haematology;2023-06-26